About this trial
This prospective, randomized clinical trial aims to evaluate the effect of preoperative nebulized lidocaine and nebulized 3% hypertonic sodium chloride (NaCl) on the incidence of postoperative respiratory complications in pediatric patients undergoing adenoidectomy and/or adenotonsillectomy. Lidocaine, a versatile sodium channel blocker, has shown antitussive, bronchodilatory, and anti-inflammatory benefits when nebulized, and has been safely used in children for respiratory procedures. Hypertonic 3% NaCl is known to improve mucociliary clearance, reduce airway edema, and enhance secretion mobilization, particularly in pediatric respiratory conditions. Both agents have demonstrated individual safety and efficacy in respiratory management, yet their preoperative nebulized use for preventing postoperative respiratory adverse events (PRAEs) in pediatric airway surgery has not been previously studied. This trial seeks to determine whether preoperative nebulization with these agents can reduce postoperative respiratory complications, improve recovery, and enhance perioperative safety in this high-risk population.
Eligibility criteria
Qualifiers
Patients who agree to participate in the study
Patients undergoing adenoidectomy or adenotonsillectomy
Patients with ASA physical status 1-2
Children aged 18 months to 16 years
Disqualifiers
Patients who do not agree to participate in the study
Patients with allergy to lidocaine or 3% NaCl
Patients with ASA physical status 3-4
Patients whose surgery duration exceeds 1 hour
Trial design
Treatments tested in this trial
- Nebulize Lidocaine
- Nebulize %3 Sodium Chloride